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ABSTRACT
Cytomegalovirus (CMV) infection is a major complication after allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT); however, we have little information on the clinical association of various human leukocyte
antigen (HLA) alleles with CMV infection. We reviewed medical records of 60 patients who underwent
allo-HSCT. The effect of the 7 most frequent HLA alleles on the incidence of CMV infection and disease was
analyzed, including HLA-A*02, A*11, A*24, B*13, B*40(60), DRB1*15, and DRB1*09. All the patients were
monitored for CMV infection at least once weekly within 3 months. CMV infection was found in 38 (63.3%)
patients on a median of day 36 (range: 16-89). Diagnosis of CMV disease was established in 6 (10.0%) patients,
comprising pneumonia (n  2), enterocolitis (n  2), and hemorrhagic cystitis (n  2). CMV disease was
successfully treated using ganciclovir or foscarnet combined with immune globulins in 4 patients. The other
2 patients died without improvement of CMV disease. In multivariate analysis, grade II-IV acute graft-versus-
host disease (aGVHD), CMV seronegative donors, and HLA-DRB1*09 were associated with increased inci-
dence of CMV infection and disease after allo-HSCT. We suggest that more cautions should be taken to
prevent CMV infection in patients with HLA-DRB1*09 after allo-HSCT.
© 2007 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Cytomegalovirus (CMV) infection still remains a
major cause of morbidity and mortality after alloge-
neic hematopoietic stem cell transplantation (allo-
HSCT) because of the delayed recovery of T and B
cell functions. Previous studies have determined sev-
eral risk factors for active CMV infection, including
the pretransplantation serostatus of the recipient and
the donor, the grade of human leukocyte antigen
(HLA) disparity, acute graft-versus-host disease
(aGVHD), and CMV-speciﬁc T cell immunodeﬁ-
ciency [1-6].
HLA molecules play a critical role in immune
responses. Some HLA antigens have been demon-
strated to be closely correlated with incidence of par-
ticular diseases, such as HLA-B27 with ankylosing
spondylitis [7]. However, the effect of various HLAantigens on CMV infection and disease after allo-
HSCT remains unclear. This study was aimed to
analyze the incidence of CMV infection and disease in
patients with various HLA alleles after allo-HSCT.
Considering the sample size, the most 7 frequent
alleles were included: HLA-A*02, A*11, A*24, B*13,
B*40(60), DRB1*15, and DRB1*09 [8].
MATERIALS AND METHODS
Patients
We reviewed the medical records of 60 patients
who underwent allo-HSCT at Peking University First
Hospital between March 2003 and December 2006.
The study was approved by the Ethical Review Board
of Peking University. The patients’ characteristics are
shown in Table 1.1417
1418Forty-seven patients were conditioned with Busulfan
and cyclophosphamide (Bu/Cy) regimen consisting of
cytarabine 2 g/m2/day intravenously on days10 to9;
busulfan 4 mg/kg/d orally on days8 to6; cyclophos-
phamide 1.8 g/m2/d intravenously on days 5 to 4,
Me-CCNU 250 mg/m2 orally once on day 3. Other
patients received Cy/Fludarabine (Flu)/antithymocyte
globulin (ATG) or TBI/Flu regimen.
Cyclosporine A (CSA) and short-term methotrexate
(MTX) were administered for prophylaxis of aGVHD.
Table 1. Patients’ Characteristics
Characteristic Number
Number of CMV
Infections (%)
Age (year)
020 20 13 (65.0)
2140 31 18 (58.1)
4160 9 7 (77.8)
Sex: male/female 35/25 22 (62.9)/16 (64.0)
Underlying disease
Acute myelogenous leukemia 19 11 (57.9)
Acute lymphocytic leukemia 7 5 (71.4)
Chronic myelogenous leukemia 19 13 (68.4)
Myelodysplastic syndrome 6 5 (83.3)
Severe aplastic anemia 3 1 (33.3)
non-Hodgkin lymphoma 4 2 (50.0)
Others 2 1 (50.0)
Donor type
Matched sibling 19 9 (47.4)
Matched unrelated 5 4 (80.0)
Mismatched family 27 16 (59.3)
Mismatched unrelated 9 9 (100)
Stem cell source
Bone marrow (BM) 2 1 (50.0)
Peripheral blood stem
cells (PBSC) 3 2 (66.7)
BM  PBSC 47 29 (61.7)
Cord blood 8 6 (75.0)
HLA antigen disparity
0 24 13 (54.2)
1 11 7 (63.6)
2 22 16 (72.7)
3 3 2 (66.7)
CMV serologic status
donor /recipient  35 20 (57.1)
donor /recipient  8 5 (62.5)
donor /recipient  17 13 (76.5)
aGVHD
Grade 0-I 38 22 (57.9)
Grade II-IV 22 16 (72.7)
Conditioning regimen
BU/CY 47 31 (65.9)
Others 13 7 (53.8)
HLA-A
*02/non *02 24/36 16 (66.7)/22 (61.1)
*11/non *11 15/45 7 (46.7)/31 (68.9)
*24/non *24 11/49 5 (45.4)/33 (67.3)
HLA-B
*13/non *13 10/50 6 (60.0)/32 (64.0)
*40(60)/non *40(60) 9/51 6 (66.7)/32 (62.7)
HLA-DRB1
*09/non *09 15/45 13 (86.7)/25 (55.6)
*15/non *15 15/45 8 (53.3)/30 (66.7)Clinical grading of aGVHD was determined accord-
ing to the suggested criteria [9]. For CMV prophylaxis,
ganciclovir (5 mg/kg twice daily) was routinely adminis-
trated intravenously from days 10 to 2.
Engraftment
Neutrophil engraftment was deﬁned as absolute
neutrophil count 0.5  109/L for 3 consecutive days
and platelet engraftment as 20  109/L for 7 con-
secutive days without transfusion. Granulocyte-colony
stimulating factor (G-CSF) was administered.
Definition of CMV Infection and Disease
The patients were monitored at least once weekly
from engraftment until day 90 after allo-HSCT.
“CMV infection” was deﬁned as the detection of
CMV DNA (500 copies /L) in peripheral blood by
quantitative real-time PCR kit (Sino-American Bio-
technology Co., China).
“CMV disease” was deﬁned according to Ljung-
man et al [10]. Brieﬂy, “CMV pneumonia” was diag-
nosed when either a bronchoalveolar lavage or a lung
biopsy was positive for CMV in a patient with char-
acteristic symptoms and chest radiographic ﬁndings;
“CMV enterocolitis” was diagnosed by gastrointesti-
nal symptoms with histologic demonstration of CMV
on biopsy materials obtained by endoscopy; “CMV
cystitis” was deﬁned by the identiﬁcation of conven-
tional histologic features of CMV infection together
with immunohistochemical analysis for CMV on a
bladder biopsy specimen obtained from a patient with
hemorrhagic cystitis. Immunohistochemical analysis
was performed using CMV pp65 monoclonal ﬂuores-
cence Brite kit (IQ Co., Holland) according to the
manufacturer’s instructions.
Therapy of CMV Infection and Disease
Once CMV infection was diagnosed, ganciclovir
was given 5 mg/kg twice daily intravenously for dura-
tion of 2 to 3 weeks as preemptive treatment. When
treating CMV disease, ganciclovir was used in combi-
nation with immune globulins (500 mg/kg every other
day for 2 weeks). If not effective or when white blood
cells decreased severely as a result of ganciclovir ad-
ministration, foscarnet was used 120-180 mg/kg/d in-
travenously together with immune globulins.
Statistical Analysis
Potential factors considered in the analysis were
patient’s age, sex, diagnosis, conditioning regimen,
stem cell source, donor type, aGVHD, CMV sero-
logic status of recipients and donors, HLA disparity,
and HLA allele. The inﬂuence of these factors on the
incidence of CMV infection and disease was evaluated
with multivariate analysis using backward stepwise
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considered statistically signiﬁcant.
RESULTS
Clinical Outcomes
All patients achieved full engraftment. The me-
dian time for neutrophil and platelet engraftment was
12 (range: 1024) and 13.5 (range: 936) days, re-
spectively. Twelve (20%) and 4 (6.7%) patients died of
transplant-related causes and disease relapse, respec-
tively, within 90 days of allo-HSCT. Twenty-two
(36.7%) patients developed grade II-IV aGVHD.
CMV infection was found in 38 (63.3%) patients
on a median of day 36 (range: 16-89). Diagnosis of
CMV disease was established in 6 (10.0%) patients;
the diagnosis comprised pneumonia (n  2), entero-
colitis (n  2), and cystitis (n  2). Enterocolitis and
cystitis were successfully treated. The remaining 2
patients who had CMV pneumonia died without im-
provement of CMV disease. The 2 patients who died
also had lung bacterial and fungal infections.
Risk Factors for CMV Infection
Multivariate analyses for CMV infection were
shown in Table 2. Patient’s age, sex, diagnosis, donor
type, stem cell source, and conditioning regimen did
not affect the incidence of CMV infection. HLA dis-
parity, CMV serologic status, aGVHD Grade II-IV,
and HLA allele type had much to do with the inci-
dence of CMV infection.
HLA disparity seemed to be positively associated
with CMV infection, although no signiﬁcance was
obtained (P  .065). Patients who were CMV sero-
positive but had negative donors were slightly more
likely to develop CMV infection (13 of 17; 76.5%)
than were seropositive patients with seropositive do-
nors (20 of 35; 57.1%) or seronegative patients with
seropositive donors (5 of 8; 62.5%).
aGVHD grade II-IV was also positively associated
with CMV infection (relative risk, 3.79; CI 0.94-15.87;
P .059). Patients with aGVHD grade II-IV were more
likely to develop CMV infection (16 of 22; 72.7%) than
were patients with aGVHD grade 0-I (22 of 38; 57.9%).
HLA-A*11 and A*24 were negatively associated
with CMV infection, but no signiﬁcance was achieved
Table 2. Multivariate Analyses for the Incidence of CMV Infection
Factor Relative Risk (95% CI) P -Value
HLA-A*11 0.28 (0.10-1.07) .064
HLA-A*24 0.22 (0.06-1.13) .059
HLA-DRB1*09 8.86 (1.13-65.38) .038
HLA disparity 1.80 (0.92-3.58) .065
CMV serologic status 2.31 (1.14-4.91) .061
aGVHD (grade II-IV) 3.79 (0.94-15.87) .059(P  .064 and .059, respectively). HLA-A*02, B*13,
B*40(60), and DRB1*15 were not closely associated
with CMV infection.
HLA-DRB1*09 allele was a risk factor for CMV
infection (relative risk, 8.86; CI 1.13-65.38; P  .038).
Patients with HLA-DRB1*09 allele were more likely
to develop CMV infection (13 of 15; 86.7%) than
were patients without HLA-DRB1*09 allele (25 of 45;
55.6%).
Risk Factors for CMV Disease
Multivariate analyses for CMV disease were
shown in Table 3. aGVHD grade II-IV and HLA-
DRB1*09 allele were positively associated with the
incidence of CMV disease, although no signiﬁcance
was achieved (P  .05), probably because the sample
size was relatively small. Patients with the HLA-
DRB1*09 allele were more likely to develop CMV
disease (3 of 15; 20.0%) than patients without the
HLA-DRB1*09 allele (3 of 45; 6.7%). Also, patients
with aGVHD grade II-IV were more likely to develop
CMV disease (4 of 22; 18.2%) than were patients with
aGVHD grade 0-I (2 of 38; 5.3%).
DISCUSSION
The clinical signiﬁcance of human leukocyte an-
tigen (HLA) allele compatibility has been well recog-
nized in patients receiving a marrow transplant [11-
14]. HLA class I (A, B, and/or C) allele mismatch
often reduces overall survival (OS) remarkably. How-
ever, the association of a particular HLA allele with
the incidence of CMV infection after allo-HSCT has
not been well established. In the present study, the
effect of 7 frequent HLA alleles on CMV infection
following allo-HSCT was analyzed and HLA-DRB1*09
was found to be a risk factor for CMV infection and
disease. In 1997, Wada et al [15] developed an en-
zyme-linked immunosorbent assay (ELISA) to detect
antibodies against antigenic domain 1 (AD-1) of hu-
man CMV, which was the major domain recognized
by neutralizing antibodies. They observed that sub-
jects with HLA-DR9 had a higher positive rate (13 of
14  92.9%) than those without HLA-DR9 (25 of
43 58.1%). More studies are needed in the future to
elucidate the role of HLA-DR9 antigen in CMV im-
mune response.
As expected, aGVHD grade II-IV was a risk factor
for CMV infection and disease. Meyers et al [16]
reported that the incidence of CMV infection in pa-
Table 3. Multivariate Analyses for the Incidence of CMV Disease
Factor Relative Risk (95% CI) P-Value
HLA-DRB1*09 5.22 (0.79-36.25) .075
aGVHD (grade II-IV) 6.03 (0.72-51.24) .068
J. Du et al.1420tients with GVHD grade 0-I and grade II-IV was
42.1% and 63.1%, respectively. Our results were
higher than that, partly because the quantitative real-
time PCR we used was more sensitive. GVHD results
in lower T cell repertoire (TCR) diversity and thymic-
dependent naive T cell output, and hence adversely
affects CMV-speciﬁc immunity [17-20]. Patients with
aGVHD grade II-IV were more prone to CMV dis-
ease, and many patients developed repeated episodes
of CMV infection despite use of antiviral drugs sup-
porting previous data that CMV-speciﬁc T cell im-
munity plays a key role in CMV control [6,21,22].
Therefore, prevention of GVHD may reduce the in-
cidence of CMV infection and infusion of CMV-
speciﬁc CD8 T cells may be a good alternative for
CMV therapy.
Furthermore, we noticed that patients who re-
ceived cord blood transplant and unrelated transplant
both had higher incidence of CMV infection, al-
though no signiﬁcance had been obtained (see Table
1). This was in agreement with previous ﬁndings
[4,23]. Higher risk of CMV infection may reﬂect the
delay in myeloid recovery in cord blood transplanta-
tion with respect to BM/PBSC transplantation
[24,25]. ATG is more frequently used to prevent
GVHD in patients receiving unrelated transplant.
ATG results in lower immunity, which may partly
explain the higher incidence of CMV infection in
patients receiving unrelated transplants.
We found HLA-DRB1*09 to be a high risk factor
for CMV infection and disease after allo-HSCT for
the ﬁrst time. Therefore, more cautions should be
taken to prevent CMV infection in patients with
HLA-DRB1*09 after allo-HSCT. Our sample size
was relatively small. A larger study is needed to con-
ﬁrm the association of HLA-DRB1*09 with CMV.
Other HLA alleles that were not analyzed in the
present study also need to be addressed.
ACKNOWLEDGMENTS
This study was supported by National Natural
Science Fund (no. 30470739).
REFERENCES
1. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett
AJ. Early reactivation of cytomegalovirus and high risk of in-
terstitial pneumonitis following T-depleted BMT for adults
with hematological malignancies. Bone Marrow Transplant.
1996;18:347-353.
2. Hebart H, Brugger W, Grigoleit U, et al. Risk for cytomega-
lovirus disease in patients receiving polymerase chain reaction-
based preemptive antiviral therapy after allogeneic stem cell
transplantation depends on transplantation modality. Blood.
2001;97:2183-2185.3. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for
the development of cytomegalovirus disease after allogeneic
stem cell transplantation. Haematologica. 2006;91:78-83.
4. Parody R, Martino R, Rovira M, et al. Severe infections after
unrelated donor allogeneic hematopoietic stem cell transplan-
tation in adults: comparison of cord blood transplantation with
peripheral blood and bone marrow transplantation. Biol Blood
Marrow Transplant. 2006;12:734-748.
5. Matsumura T, Narimatsu H, Kami M, et al. Cytomegalovirus
infections following umbilical cord blood transplantation using
reduced intensity conditioning regimens for adult patients. Biol
Blood Marrow Transplant. 2007;13:577-583.
6. Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based
quantiﬁcation of cytomegalovirus (CMV)-speciﬁc CD8 T
lymphocytes in T-cell-depleted stem cell grafts and after trans-
plantation may identify patients at risk for progressive CMV
infection. Blood. 2001;98:1358-1364.
7. Khan MA. HLA-B27 polymorphism and association with dis-
ease. J Rheumatol. 2000;27:1110-1114.
8. Wu QJ, Liu ML, Qi J, Liu S, Zhang Y, Wei XQ. Gene and
haplotype frequencies for the loci HLA-A, B and DRB1 in
11755 north Chinese Han bone marrow registry donors. J Exp
Hematol. 2007;15:357-363 (in Chinese).
9. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of
graft-versus-host disease in human recipients of marrow from
HLA-match sibling donors. Transplantation. 1974;18:295-304.
10. Ljungman P, Grifﬁths P, Paya C. Deﬁnitions of cytomegalo-
virus infection and disease in transplant recipients. Clin Infect
Dis. 2002;34:1094-1097.
11. Morishima Y, Sasazuki T, Inoko H, et al. The clinical signiﬁ-
cance of human leukocyte antigen (HLA) allele compatibility in
patients receiving a marrow transplant from serologically
HLA-A, HLA-B, and HLA-DR matched unrelated donors.
Blood. 2002;99:4200-4206.
12. Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplanta-
tion from unrelated donors for the treatment of hematological
malignancies: effect of mismatching for one HLA locus. Blood.
1993;81:249-253.
13. Petersdorf EW, Longton GM, Anasetti C, et al. The signiﬁ-
cance of HLA-DRB1 matching on clinical outcome after
HLA-A, B, DR identical unrelated donor marrow transplanta-
tion. Blood. 1995;86:1606-1613.
14. Ringden O, Schaffer M, Le Blanc K, et al. Which donor should
be chosen for hematopoietic stem cell transplantation among
unrelated HLA-A, -B, and -DRB1 genomically identical vol-
unteers? Biol Blood Marrow Transplant. 2004;10:128-134.
15. Wada K, Mizuno S, Ohta H, Nishiyama Y. Immune response
to neutralizing epitope on human cytomegalovirus gylcoprotein
B in Japanese: correlation of serologic response with HLA-type.
Microbiol Immunol. 1997;41:841-845.
16. Meyers JD, Flournoy N, Thomas ED. Risk factors for cyto-
megalovirus infection after human bone marrow transplanta-
tion. J Infect Dis. 1986;153:478-488.
17. Tsutsumi Y, Tanaka J, Miura Y, et al. Molecular analysis of
T-cell repertoire in patients with graft-versus-host disease after
allogeneic stem cell transplantation. Leuk Lymphoma. 2004;45:
481-488.
18. Liu C, Min H, Barbara R, Thomas BK, Nelson JC. Longitu-
dinal analysis of T-cell receptor variable chain repertoire in
patients with acute graft-versus-host disease after allogeneic
stem cell transplantation. Biol Blood Marrow Transplant. 2006;
12:335-345.
19. Fallen PR, McGreavey L, Madrigal JA, et al. Factors affecting
reconstitution of the T cell compartment in allogeneic haema-
topoietic cell transplant recipients. Bone Marrow Transplant.
2003;32:1001-1014.
20. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting
thymic function after allogeneic hematopoietic stem cell trans-
plantation. Blood. 2001;97:1458-1466.
21. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalo-
virus (CMV)-speciﬁc T cells for the treatment of CMV infec-
tion not responding to antiviral chemotherapy. Blood. 2002;99:
3916-3922.
22. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalo-
virus disease and mortality in recipients of allogeneic hemato-
HLA-DRB1*09 with Cytomegaloviruspoietic stem cell transplants: importance of viral load and T-cell
immunity. Blood. 2003;101:407-414.
23. Jia JS, Liu DP, Huang XJ, et al. Survellance of cytomegalovirus
for antiviral efﬁcacy and risk factors in allogeneic hematopoietic
stem cell transplantation. J Exp Hematol. 2006;14:749-754 (in
Chinese).
24. Saavedra S, Sanz GF, Jarque I, et al. Early infections in adult
patients undergoing unrelated donor cord blood transplanta-
tion. Bone Marrow Transplant. 2002;30:937-943.
25. Barker JN, Hough RE, van Burik JA, et al. Serious infec-
tions after unrelated donor transplantation in 136 children:
impact of stem cell source. Biol Blood Marrow Transplant. 2005;
11:362-370.
1421
